This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Berruti, A. Articles by Dogliotti, L. Search for Related Content PubMed PubMed Citation Articles by Berruti, A. Articles by Dogliotti, L. Social Bookmarking                            What's this?

Time to Progression in Metastatic Breast Cancer Patients Treated With Epirubicin Is Not Improved by the Addition of Either Cisplatin or Lonidamine: Final Results of a Phase III Study With a Factorial Design

From Oncologia Medica, Azienda Ospedaliera San Luigi, Orbassano; Centro di Senologia, Azienda Ospedaliera Istituti Ospitalieri, Cremona; Endocrinologia Oncologica, Istituto Tumori Fondazione Pascale, Napoli; Clinica Ostetrica e Ginecologica, Azienda Ospedaliera Sant’Anna; Ginecologia Oncologica, Azienda Ospedaliera Sant’Anna; and Oncologia Medica Ospedale San Giovanni, Torino; Oncologia Medica, Istituto Oncologico, Bari; Oncologia Medica, Istituto Clinica Medica Universitaria, Sassari; Chirurgia Generale IV, Azienda Ospedaliera San Giovanni Battista; Oncologia Medica, Ospedale San Lazzaro, Alba; Radioterapia, Ospedale degli Infermi, Biella; Ginecologia, Ospedale SS Annunziata, Savigliano; and Servizio di Epidemiologia Clinica, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.

Address reprint requests to Luigi Dogliotti, MD, PhD, Oncologia Medica, Azienda Ospedaliera San Luigi, Regione Gonzole 10, 10043 Orbassano, Torino, Italy; email: luigi.dogliotti{at}unito.it

PURPOSE: To investigate the value of the addition of either cisplatin (CDDP) or lonidamine (LND) to epirubicin (EPI) in the first-line treatment of advanced breast cancer.

PATIENTS AND METHODS: Three hundred seventy-one metastatic breast cancer patients with no prior systemic chemotherapy for advanced disease were randomized to receive either EPI alone (60 mg/m² on days 1 and 2 every 21 days), EPI and CDDP (30 mg/m² on days 1 and 2 every 21 days), EPI and LND (450 mg orally daily, given continuously), or EPI, CDDP, and LND. Time to progression, response rates, side effects, and survival were compared according to the 2 x 2 factorial design of this study.

RESULTS: The groups were well balanced with respect to prognostic factors. Time to progression did not differ in the comparison between CDDP arms and non-CDDP arms (median, 10.9 months v 9.4 months, respectively; P = .10) or between that of LND arms and non-LND arms (median, 10.8 months v 9.9 months, respectively; P = .47), nor did overall survival. The response rate did not significantly differ in the comparison between LND arms and non-LND arms (62.9% v 54.0%, P = .08). No difference in treatment activity was observed between CDDP arms and non-CDDP arms. Toxicity was significantly higher in the CDDP arms, leading to CDDP dose adjustment in 40% of cases. The most frequent side effects were of a hematologic and gastrointestinal nature. The addition of LND produced more myalgias and fatigue.

CONCLUSION: Neither CDDP nor LND was able to significantly improve the time to progression obtained by EPI. CDDP, however, significantly worsened the drug’s tolerability.

Presented in part at the Thirty-Sixth Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, May 19-23, 2000.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. D. Saad and A. Katz Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined Ann. Onc., March 1, 2009; 20(3): 460 - 464. [Abstract] [Full Text] [PDF]

				D. Mauri, N. P. Polyzos, G. Salanti, N. Pavlidis, and J. P. A. Ioannidis Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer J Natl Cancer Inst, December 17, 2008; 100(24): 1780 - 1791. [Abstract] [Full Text] [PDF]

				P. Papaldo, M. Lopez, P. Marolla, E. Cortesi, M. Antimi, E. Terzoli, P. Vici, C. Barone, G. Ferretti, S. Di Cosimo, et al. Impact of Five Prophylactic Filgrastim Schedules on Hematologic Toxicity in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide J. Clin. Oncol., October 1, 2005; 23(28): 6908 - 6918. [Abstract] [Full Text] [PDF]

				B. Ejlertsen, H. T. Mouridsen, S. T. Langkjer, J. Andersen, J. Sjostrom, and M. Kjaer Phase III Study of Intravenous Vinorelbine in Combination With Epirubicin Versus Epirubicin Alone in Patients With Advanced Breast Cancer: A Scandinavian Breast Group Trial (SBG9403) J. Clin. Oncol., June 15, 2004; 22(12): 2313 - 2320. [Abstract] [Full Text] [PDF]

				P. Papaldo, M. Lopez, E. Cortesi, E. Cammilluzzi, M. Antimi, E. Terzoli, G. Lepidini, P. Vici, C. Barone, G. Ferretti, et al. Addition of Either Lonidamine or Granulocyte Colony-Stimulating Factor Does Not Improve Survival in Early Breast Cancer Patients Treated With High-Dose Epirubicin and Cyclophosphamide J. Clin. Oncol., September 15, 2003; 21(18): 3462 - 3468. [Abstract] [Full Text] [PDF]

				A. D. Seidman Sequential Single-Agent Chemotherapy for Metastatic Breast Cancer: Therapeutic Nihilism or Realism? J. Clin. Oncol., February 15, 2003; 21(4): 577 - 579. [Full Text] [PDF]